Organon & Co. (OGN)

Market Cap	2.98B
Revenue (ttm)	6.40B
Net Income (ttm)	864.00M
Shares Out	257.95M
EPS (ttm)	3.33
PE Ratio	3.47
Forward PE	3.00
Dividend	$1.12 (9.70%)
Ex-Dividend Date	Feb 24, 2025

Volume	355,447
Open	11.59
Previous Close	11.49
Day's Range	11.45 - 11.59
52-Week Range	10.45 - 23.10
Beta	0.69
Analysts	Hold
Price Target	20.60 (+78.51%)
Earnings Date	May 1, 2025

About OGN

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 10,000
• Stock Exchange: NYSE
• Ticker Symbol: OGN
• Website: https://www.organon.com

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Analyst Forecast

According to 5 analysts, the average rating for OGN stock is "Hold." The 12-month stock price forecast is $20.6, which is an increase of 78.51% from the latest price.

Price Target

$20.6

(78.51% upside)

Analyst Consensus: Hold